Ipamorelin has something most research peptides lack: a Phase III trial. It also has what usually follows one that fails. The trial missed its endpoint, development stopped, and zero randomized trials cover the uses it is sold for.
Ipamorelin is a five-amino-acid peptide. It tells the pituitary to release growth hormone, through the ghrelin receptor GHS-R1a. Its selectivity is real: cortisol, prolactin and ACTH barely move. Its clinical record is one Phase III trial, in postoperative ileus. It missed its endpoint. Development stopped. Zero randomized trials cover muscle, fat, aging or repair. WADA bans it under S2.
The trial that ran, and the one nobody ran
Ipamorelin was developed as a drug, properly, by a pharmaceutical company. It reached a Phase III trial. The indication was postoperative ileus, the temporary shutdown of gut motility after abdominal surgery, which is a real clinical problem and a reasonable target for a ghrelin-receptor agonist.
The trial missed its primary endpoint. Development on the drug then stopped.
There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.
Beck et al., International Journal of Colorectal Disease, 2014That is the entire controlled human record. Nothing was ever randomized for muscle gain, fat loss, sleep, recovery or aging — the four things ipamorelin is actually bought for. Not a failed trial in those areas. No trial at all.
The ipamorelin complete guide covers the development history and what the discontinuation implies.
What the selectivity claim does and does not buy
The strongest thing anyone can say about ipamorelin is true, and it is a pharmacology claim rather than an outcome claim.
Ipamorelin, the first selective growth hormone secretagogue.
Raun et al., European Journal of Endocrinology, 1998It hits GHS-R1a and largely leaves the rest alone. Cortisol, prolactin, ACTH and aldosterone stay near baseline, which is a real advantage over the older secretagogues and the reason clinicians found it interesting.
But a clean receptor profile describes what a compound does not do. It is not evidence of benefit, and it does not substitute for an endpoint. This is the same distinction that runs through CJC-1295 vs ipamorelin.
Why growth-hormone photos are the hardest to read
Body-composition before-and-afters from GH-axis compounds have a structural problem beyond the usual ones.
- Almost nobody runs it alone. Ipamorelin is usually stacked, most often with CJC-1295, so any change has at least two candidate causes.
- Water retention is an early GH effect and it changes how someone looks well before body composition does.
- Appetite moves. Ghrelin-receptor agonism increases hunger, which changes intake, which changes the photo independently of the peptide.
- Training changes at the same time. The usual confound, and it is the strongest one. See CJC-1295 and ipamorelin dosage.
None of that means nothing happened. It means the photo cannot tell you what did.
Ipamorelin
The selective secretagogue discussed here, supplied as a research compound with a batch-matched certificate of analysis.
What a GH-axis result looks like when it exists
There is a compound in this class with a real measured before and after, and the comparison is instructive. Tesamorelin reduced visceral fat by 15.2% on CT over 26 weeks, against a 5.0% gain on placebo, in 412 randomized adults.
Two things stand out. The change was measured by a scanner rather than a camera. And it is smaller than the internet implies for compounds with no data at all, which is the usual pattern: measured effects come in below marketed ones.
The safety and efficacy of growth hormone secretagogues.
Sigalos & Pastuszak, Sexual Medicine Reviews, 2018That review is the standard reference for this class, and it is a review of safety and pharmacology rather than a catalog of outcomes, because the outcome studies were not run. The GH axis overview covers the class.
Competition status
Worth stating clearly on a results page, because the people most interested in results are often the people most affected by this.
WADA prohibits ipamorelin under S2, the peptide hormones and growth factors category. It is prohibited at all times, in and out of competition. A tested athlete should treat any before-and-after discussion of this compound as academic.
Three things follow from that status:
- It is prohibited in and out of competition. There is no window in which a tested athlete can use it.
- Detection is not the constraint people assume. Peptide hormones are a mature testing area.
- A blend does not hide it. Stacking with CJC-1295 adds a second listed compound rather than masking the first.
Are peptides legal covers the wider regulatory position. Verify current status with the relevant governing body rather than with a vendor.
Ipamorelin
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- Its only real trial failed. A Phase III study in postoperative ileus missed its endpoint and development stopped.
- Zero randomized trials cover muscle, fat, aging or tissue repair — the uses it is actually sold for.
- The selectivity is real: cortisol, prolactin, ACTH and aldosterone barely move. That is a pharmacology claim, not an outcome.
- It is almost always stacked with CJC-1295, so any personal result has at least two candidate causes.
- WADA prohibits it under S2, at all times, in and out of competition.
What we're watching
A discontinued Phase III asset rarely comes back, and nothing suggests this one will. The realistic path to a number here is academic rather than commercial: a small randomized trial on body composition or sleep architecture, which the compound's clean receptor profile would make straightforward to run safely. Nobody has announced one. Until then, the only measured ipamorelin endpoint on record is the one it missed.
Frequently asked questions
Does ipamorelin have real before and after results?
Not for the uses it is sold for. Zero randomized trials cover muscle, fat, aging or recovery. The one controlled human trial was a Phase III study in postoperative ileus, and it missed its endpoint.
What happened to ipamorelin as a drug?
It reached Phase III for postoperative ileus, failed to hit its primary endpoint, and development stopped. That is unusually far through clinical development for a compound now sold as a research peptide.
How long does ipamorelin take to work?
There is no measured timeline for the outcomes people buy it for, because no trial measured them. Growth hormone release itself is pulsatile and rapid, but a hormone response is not a body-composition result.
Is ipamorelin better than CJC-1295?
No head-to-head outcome trial exists, so the comparison is pharmacological rather than evidential. Ipamorelin is more receptor-selective. Neither has randomized outcome data for muscle, fat or aging.
Is ipamorelin banned in sport?
Yes. WADA prohibits it under S2, the peptide hormones and growth factors category, at all times. Verify current status with the relevant governing body.
References
- Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
- Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
- Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
- ClinicalTrials.gov. Phase II double-blind placebo-controlled dose-finding study to evaluate safety/efficacy of ipamorelin compared to placebo for recovery of gastrointestinal function following bowel resection (NCT01280344). No results posted. https://clinicaltrials.gov/study/NCT01280344
- Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
- Beck, D. E., Sweeney, W. B., McCarter, M. D., & the Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
- Sigalos, J. T., & Pastuszak, A. W. (2018). The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews, 6(1), 45–53. https://doi.org/10.1016/j.sxmr.2017.02.004
- Sinha, D. K., Balasubramanian, A., Tatem, A. J., et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 9(Suppl 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30
- Bowers, C. Y. (2012). History to the discovery of ghrelin. Methods in Enzymology, 514, 3–32. https://doi.org/10.1016/b978-0-12-381272-8.00001-5